Company: CMND
Filing Date: 2025-09-15
Form Type: POS AM
Source: 0001213900-25-087398
Chunk: 34

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-15
Form: POS AM
Chunk 34
---
 | Under the BCBCA, qualified shareholders                                                                                              
 holding at least one percent (1%) of our issued voting shares or whose shares have a fair market value in excess of $2,000 in        
 the aggregate may make proposals for matters to be considered at the annual general meeting of shareholders. Such proposals must     
 be sent to us in advance of any proposed meeting by delivering a timely written notice in proper form to our registered office in    
 accordance with the requirements of the BCBCA. The notice must include information on the business the shareholder intends to bring  
 before the meeting. To be a qualified shareholder, a shareholder must currently be and have been a registered or beneficial owner    
 of at least one share of the company for at least 2 years before the date of signing the proposal.   If the proposal and a written   
 statement in support of the proposal (if any) are submitted at least three months before the anniversary date of the previous annual 
 meeting and the proposal and written statement (if any) meet other specified requirements, then the company must either set out the  
 proposal, including the names and mailing addresses of the submitting person and supporters and the written statement (if any), in   
 the proxy circular of the company or attach the proposal and written statement thereto.   In certain circumstances, the company      
 may refuse to process a proposal.                                                                                                    |

<div align='center'>23

DESCRIPTION OF WARRANTS</div>

January 2024 PIPE Warrants

The following is a brief
summary of the January 2024 PIPE Warrants issued in the January 2024 Private Placement and is subject in all respects to the provisions
contained in the investor warrants, in the form filed as an exhibit to our Current Report on Form 6-K dated January 16, 2024.

Exercisability. The January 2024 PIPE Warrants
are exercisable at any time after their original issuance and at any time up to the date that is five years after their original issuance.
The January 2024 PIPE Warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed
exercise notice and, at any time a registration statement registering the issuance of the common shares underlying the January 2024 PIPE
Warrants under the Securities Act is effective and available for the issuance of such shares, by payment in full in immediately available
funds for the number of common shares purchased upon such exercise. We will make our best effort to maintain an effective registration
statement